Anti-tubercular treatment-induced granulomatous acute interstitial nephritis

Indian J Pharmacol. 2024 Jul 1;56(4):290-292. doi: 10.4103/ijp.ijp_19_24. Epub 2024 Sep 10.

Abstract

This case emphasizes the value of meticulous observation and regular follow-up of patients receiving rifampicin therapy. The prognosis for complete improvement in renal function in such cases was excellent, with prompt recognition and discontinuation of rifampicin. Teaching patients about these possible adverse effects and encouraging immediate reporting of signs and symptoms are likely to be beneficial because acute kidney injury can manifest itself very quickly after rifampicin is started. Even if renal failure can happen with any dose of rifampicin, primary physicians must have awareness about patients on intermittent or irregular therapy and those who have previously used this medication. It is challenging to determine the prevalence of adverse reactions to common antibiotics where a state- or country-wide reporting system is absent. Along with withdrawal of the causative agent patients were treated with corticosteroids (0.5-1 mg/kg/day) for an average period of 4-12 weeks showing significant recovery of renal function.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adult
  • Antitubercular Agents* / adverse effects
  • Antitubercular Agents* / therapeutic use
  • Female
  • Granuloma / chemically induced
  • Granuloma / drug therapy
  • Humans
  • Male
  • Nephritis, Interstitial* / chemically induced
  • Rifampin* / adverse effects
  • Rifampin* / therapeutic use

Substances

  • Rifampin
  • Antitubercular Agents